Infant Bacterial Therapeutics AB (publ) Total Liabilities
Infant Bacterial Therapeutics AB (publ) total liabilities. Based on the latest financial reports, Infant Bacterial Therapeutics AB (publ) (IBT-B) has total liabilities worth Skr53.87 Million SEK (≈ $5.80 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Infant Bacterial Therapeutics AB (publ) to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Infant Bacterial Therapeutics AB (publ) (2013–2024)
Total liabilities of Infant Bacterial Therapeutics AB (publ) from 2013 to 2024. This chart illustrates how Infant Bacterial Therapeutics AB (publ)'s total liabilities have evolved over time, based on quarterly financial data.
Infant Bacterial Therapeutics AB (publ) Competitors by Total Liabilities
The table below lists competitors of Infant Bacterial Therapeutics AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Atlas Resources Tbk
JK:ARII
|
Indonesia | Rp509.35 Million |
|
TCM Group
CO:TCM
|
Denmark | Dkr764.30 Million |
|
OCK Group Bhd
KLSE:0172
|
Malaysia | RM1.29 Billion |
|
Phoenix Tours International Inc
TW:5706
|
Taiwan | NT$1.31 Billion |
|
Idsud S.A
PA:ALIDS
|
France | €8.95 Million |
|
Multicampus Corporation
KQ:067280
|
Korea | ₩83.88 Billion |
|
Gandhi Special Tubes Limited
NSE:GANDHITUBE
|
India | Rs-3.16 Billion |
|
Takarék Jelzálogbank Nyrt
F:FH21
|
Germany | €682.66 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Infant Bacterial Therapeutics AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see IBT-B current and non-current assets.
Liquidity & Leverage Metrics
Infant Bacterial Therapeutics AB (publ) Total Liabilities Ratios Explained
Infant Bacterial Therapeutics AB (publ) total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Infant Bacterial Therapeutics AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Infant Bacterial Therapeutics AB (publ) (2013–2024)
The table below shows the annual total liabilities of Infant Bacterial Therapeutics AB (publ) from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr69.30 Million ≈ $7.46 Million |
+50.07% |
| 2023-12-31 | Skr46.18 Million ≈ $4.97 Million |
+157.80% |
| 2022-12-31 | Skr17.91 Million ≈ $1.93 Million |
+35.46% |
| 2021-12-31 | Skr13.22 Million ≈ $1.42 Million |
+30.11% |
| 2020-12-31 | Skr10.16 Million ≈ $1.09 Million |
+29.05% |
| 2019-12-31 | Skr7.88 Million ≈ $847.58K |
+18.36% |
| 2018-12-31 | Skr6.65 Million ≈ $716.08K |
+0.02% |
| 2017-12-31 | Skr6.65 Million ≈ $715.97K |
+36.25% |
| 2016-12-31 | Skr4.88 Million ≈ $525.49K |
-36.86% |
| 2015-12-31 | Skr7.73 Million ≈ $832.30K |
+120.59% |
| 2014-12-31 | Skr3.51 Million ≈ $377.30K |
+1356.61% |
| 2013-12-31 | Skr240.70K ≈ $25.90K |
-- |
About Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also develop… Read more